Articles with "etanercept biosimilar" as a keyword



Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis

Sign Up to like & get
recommendations!
Published in 2019 at "Advances in Therapy"

DOI: 10.1007/s12325-019-01027-z

Abstract: This study aimed to compare the usability of subcutaneous administration of SB4 (an etanercept biosimilar) via prefilled syringe (PFS) and autoinjector (AI) based on injection site pain, patient preference, and safety in patients with rheumatoid… read more here.

Keywords: sb4 etanercept; pfs; etanercept biosimilar; prefilled syringe ... See more keywords
Photo by atikahakhtar from unsplash

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Sign Up to like & get
recommendations!
Published in 2017 at "British Journal of Dermatology"

DOI: 10.1111/bjd.15152

Abstract: GP2015 is a proposed etanercept biosimilar. read more here.

Keywords: proposed etanercept; etanercept biosimilar; gp2015 proposed; study ... See more keywords
Photo from wikipedia

AB0211 SWITCHING FROM ETANERCEPT ORIGINAL TO ETANERCEPT BIOSIMILAR: LONG TERM FOLLOW UP

Sign Up to like & get
recommendations!
Published in 2021 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2021-eular.1162

Abstract: Biosimilar drugs has supposed a huge savings in our health systems and there are data that conclude that they work as original molecules when we making these switchings. There are limited studies that analize these… read more here.

Keywords: term follow; etanercept biosimilar; arthritis; long term ... See more keywords
Photo by curvd from unsplash

Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study

Sign Up to like & get
recommendations!
Published in 2022 at "Frontiers in Pediatrics"

DOI: 10.3389/fped.2022.992932

Abstract: Background Etanercept biosimilar recombinant human TNF-α receptor II: IgG Fc fusion protein (rhTNFR-Fc) has showed its efficacy and safety in Chinese patients with rheumatoid arthritis. However, data on rhTNFR-Fc's application in juvenile idiopathic arthritis (JIA)… read more here.

Keywords: etanercept biosimilar; rhtnfr; arthritis; chinese patients ... See more keywords